Literature DB >> 10820221

The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules.

M Pérez1, F Lim, M Arrasate, J Avila.   

Abstract

The recent finding that several point mutations in the gene encoding for the microtubule-binding protein tau correlate with neurological disorders has heightened interest in the mechanisms of destabilization of this protein. In this study the functional consequences of the tau mutation R406W on the interaction of the protein with microtubules have been analyzed. Mutated tau is less phosphorylated than its normal counterpart at serines 396 and 404. Furthermore, the phosphorylated mutant protein is unable to bind to microtubules, and, as a consequence, microtubules assembled after transient nocodazole treatment in the presence of this tau variant contain only unmodified tau and appear to form more and longer bundles than those assembled in the presence of wild-type tau. We propose that phosphorylated tau, unbound to microtubules, could accumulate in the cytoplasm.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820221     DOI: 10.1046/j.1471-4159.2000.0742583.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

1.  Strategies for diminishing katanin-based loss of microtubules in tauopathic neurodegenerative diseases.

Authors:  Haruka Sudo; Peter W Baas
Journal:  Hum Mol Genet       Date:  2010-11-30       Impact factor: 6.150

2.  Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation.

Authors:  T Miyasaka; M Morishima-Kawashima; R Ravid; P Heutink; J C van Swieten; K Nagashima; Y Ihara
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.

Authors:  Michael DeTure; Li-Wen Ko; Colin Easson; Shu-Hui Yen
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Increased Human Wildtype Tau Attenuates Axonal Transport Deficits Caused by Loss of APP in Mouse Models.

Authors:  Karen D B Smith; Erica Peethumnongsin; Han Lin; Hui Zheng; Robia G Pautler
Journal:  Magn Reson Insights       Date:  2010

Review 5.  Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Authors:  Jesús Avila; Filip Lim; Francisco Moreno; Carlos Belmonte; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

6.  Effect of Pin1 or microtubule binding on dephosphorylation of FTDP-17 mutant Tau.

Authors:  Kensuke Yotsumoto; Taro Saito; Akiko Asada; Takayuki Oikawa; Taeko Kimura; Chiyoko Uchida; Koichi Ishiguro; Takafumi Uchida; Masato Hasegawa; Shin-ichi Hisanaga
Journal:  J Biol Chem       Date:  2009-04-28       Impact factor: 5.157

7.  Human tau protein forms complex with PrP and some GSS- and fCJD-related PrP mutants possess stronger binding activities with tau in vitro.

Authors:  Xiao-Fan Wang; Chen-Fang Dong; Jin Zhang; Yan-Zhen Wan; Feng Li; Yin-Xia Huang; Lu Han; Bing Shan; Chen Gao; Jun Han; Xiao-Ping Dong
Journal:  Mol Cell Biochem       Date:  2007-11-25       Impact factor: 3.396

8.  Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (Cdk5)-dependent Alzheimer phosphorylation sites.

Authors:  Taeko Kimura; Koji Tsutsumi; Masato Taoka; Taro Saito; Masami Masuda-Suzukake; Koichi Ishiguro; Florian Plattner; Takafumi Uchida; Toshiaki Isobe; Masato Hasegawa; Shin-ichi Hisanaga
Journal:  J Biol Chem       Date:  2013-01-28       Impact factor: 5.157

Review 9.  Alzheimer's disease: insights from Drosophila melanogaster models.

Authors:  Aileen Moloney; David B Sattelle; David A Lomas; Damian C Crowther
Journal:  Trends Biochem Sci       Date:  2009-12-25       Impact factor: 13.807

10.  Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes.

Authors:  Alexis Bretteville; Kunie Ando; Antoine Ghestem; Anne Loyens; Séverine Bégard; Jean-Claude Beauvillain; Nicolas Sergeant; Malika Hamdane; Luc Buée
Journal:  PLoS One       Date:  2009-03-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.